BridgeMD
New treatment option for CVA (Cerebrovascular Accident)
Official title Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC
ClinicalTrials.gov ID: NCT06241677
What this study is testing
What is alteplase or tenecteplase?
alteplase or tenecteplase is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for cva (cerebrovascular accident).
Also referred to as tPA or TNK.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours
- Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or...
- National Institute of Health Stroke Scale (NIHSS) ≥ 3
- Alberta Stroke Programme Early CT (ASPECT) score ≥ 6
- Pre-morbid modified Rankin Scale (mRS) ≤ 3
You likely can't join if
- Initial CT brain showing intracranial haemorrhage
- Contraindications to IVT according to current guideline recommendations [5], except for the use of DOAC within 12-48 hours
- Patients with an estimated glomerular filtration rate of ≤ 30ml/min/1.73m2
- Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of \< 100x109/L
- Patients with significant head injury immediately prior to presentation
See the full eligibility criteria
- Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours
- Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or rivaroxaban (15mg or 20mg daily) 12-48 hours before presentation
- National Institute of Health Stroke Scale (NIHSS) ≥ 3
- Alberta Stroke Programme Early CT (ASPECT) score ≥ 6
- Pre-morbid modified Rankin Scale (mRS) ≤ 3
- Patients aged ≥ 18 years old
- Initial CT brain showing intracranial haemorrhage
- Contraindications to IVT according to current guideline recommendations [5], except for the use of DOAC within 12-48 hours
- Patients with an estimated glomerular filtration rate of ≤ 30ml/min/1.73m2
- Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of \< 100x109/L
- Patients with significant head injury immediately prior to presentation
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.